HKSE - Delayed Quote HKD

Zai Lab Limited (9688.HK)

Compare
14.580 -0.140 (-0.95%)
At close: 4:08 PM GMT+8
Loading Chart for 9688.HK
DELL
  • Previous Close 14.720
  • Open 14.940
  • Bid 14.540 x --
  • Ask 14.580 x --
  • Day's Range 14.540 - 14.940
  • 52 Week Range 10.560 - 25.750
  • Volume 3,114,900
  • Avg. Volume 6,629,674
  • Market Cap (intraday) 14.393B
  • Beta (5Y Monthly) 1.15
  • PE Ratio (TTM) --
  • EPS (TTM) -2.730
  • Earnings Date Aug 5, 2024 - Aug 9, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 39.37

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

www.zailaboratory.com

2,175

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 9688.HK

Performance Overview: 9688.HK

Trailing total returns as of 6/18/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

9688.HK
32.19%
HANG SENG INDEX
5.09%

1-Year Return

9688.HK
36.88%
HANG SENG INDEX
10.60%

3-Year Return

9688.HK
88.42%
HANG SENG INDEX
37.27%

5-Year Return

9688.HK
76.23%
HANG SENG INDEX
23.69%

Compare To: 9688.HK

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 9688.HK

Valuation Measures

Annual
As of 6/17/2024
  • Market Cap

    14.53B

  • Enterprise Value

    9.94B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.28

  • Price/Book (mrq)

    2.44

  • Enterprise Value/Revenue

    4.37

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -116.45%

  • Return on Assets (ttm)

    -21.85%

  • Return on Equity (ttm)

    -38.44%

  • Revenue (ttm)

    291.07M

  • Net Income Avi to Common (ttm)

    -338.95M

  • Diluted EPS (ttm)

    -2.730

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    650.78M

  • Total Debt/Equity (mrq)

    8.31%

  • Levered Free Cash Flow (ttm)

    -225.87M

Research Analysis: 9688.HK

Company Insights: 9688.HK

Research Reports: 9688.HK

People Also Watch